Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab

Abstract

Alemtuzumab appears to be an effective salvage agent for refractory HLH, leading to improvement and survival to HCT in many patients. Prospective trials to define optimal dosing levels, schedules, and responses are needed.